Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients

Human Immunology

Volumn 75, Issue 11, 2014, Pages 1128-1137

  Jiang, Jingwei ^a   Guo, Weijian ^b   Liang, Xiaohua ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Human; Immune suppressor cell; Myeloid derived suppressor cell; Tumor

Indexed keywords

CANCER PATIENT; CANCER THERAPY; CELL FUNCTION; CELL TYPE; HUMAN; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; MYELOID DERIVED SUPPRESSOR CELL; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REVIEW; SUPPRESSOR CELL; TARGET CELL; BONE MARROW CELL; CELL LINEAGE; DISEASE MANAGEMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT; LEUKOCYTE ANTIGEN; TUMOR PROTEIN;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CELL LINEAGE; DISEASE MANAGEMENT; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPHENOTYPING; MYELOID CELLS; NEOPLASM PROTEINS; NEOPLASMS; PHENOTYPE; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84911991603     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.09.025     Document Type: Review

References (62)

1. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
2. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58:49-59.
3. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6:1755-1766.
4. Zhang B., Wang Z., Wu L., Zhang M., Li W., Ding J., et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS ONE 2013, 8:e57114.
5. Kao J., Ko E.C., Eisenstein S., Sikora A.G., Fu S., Chen S.H. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011, 77:12-19.
6. Pak A.S., Wright M.A., Matthews J.P., Collins S.L., Petruzzelli G.J., Young M.R. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1995, 1:95-103.
7. Lathers D.M., Clark J.I., Achille N.J., Young M.R. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother 2004, 53:422-430.
8. Pandit R., Lathers D.M., Beal N.M., Garrity T., Young M.R. CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol 2000, 109:749-754.
9. Young M.R., Wright M.A., Lozano Y., Prechel M.M., Benefield J., Leonetti J.P., et al. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 1997, 74:69-74.
10. Young M.R., Petruzzelli G.J., Kolesiak K., Achille N., Lathers D.M., Gabrilovich D.I. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. Hum Immunol 2001, 62:332-341.
11. Garrity T., Pandit R., Wright M.A., Benefield J., Keni S., Young M.R. Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int J Cancer 1997, 73:663-669.
12. Zhao F., Hoechst B., Duffy A., Gamrekelashvili J., Fioravanti S., Manns M.P., et al. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology 2012, 136:176-183.
13. Trellakis S., Bruderek K., Hutte J., Elian M., Hoffmann T.K., Lang S., et al. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun 2013, 19:328-336.
14. Brandau S., Trellakis S., Bruderek K., Schmaltz D., Steller G., Elian M., et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 2011, 89:311-317.
15. Schilling B., Sucker A., Griewank K., Zhao F., Weide B., Gorgens A., et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013, 133:1653-1663.
16. Verma C., Eremin J.M., Robins A., Bennett A.J., Cowley G.P., El-Sheemy M.A., et al. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med 2013, 11:16.
17. Rodriguez P.C., Ernstoff M.S., Hernandez C., Atkins M., Zabaleta J., Sierra R., et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009, 69:1553-1560.
18. Ko J.S., Rayman P., Ireland J., Swaidani S., Li G., Bunting K.D., et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010, 70:3526-3536.
19. Zhang H., Maric I., Diprima M.J., Khan J., Orentas R.J., Kaplan R.N., et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 2013, 122:1105-1113.
20. Cui T.X., Kryczek I., Zhao L., Zhao E., Kuick R., Roh M.H., et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing MicroRNA101 and suppressing the corepressor CtBP2. Immunity 2013, 39:611-621.
21. Mandruzzato S., Solito S., Falisi E., Francescato S., Chiarion-Sileni V., Mocellin S., et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009, 182:6562-6568.
22. Wang L., Chang E.W., Wong S.C., Ong S.M., Chong D.Q., Ling K.L. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol 2013, 190:794-804.
23. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001, 166:678-689.
24. Feng S., Liu C., Zheng S., Huang P., Chen B., Guo K. Expression of myeloid-derived suppressor cells in the peripheral blood and its clinical significance in renal carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 2013, 33:550-553.
25. Vasquez-Dunddel D., Pan F., Zeng Q., Gorbounov M., Albesiano E., Fu J., et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 2013, 123:1580-1589.
26. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007, 25:2546-2553.
27. Arihara F., Mizukoshi E., Kitahara M., Takata Y., Arai K., Yamashita T., et al. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 2013, 62:1421-1430.
28. Gabitass R.F., Annels N.E., Stocken D.D., Pandha H.A., Middleton G.W. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011, 60:1419-1430.
29. Rudolph B.M., Loquai C., Gerwe A., Bacher N., Steinbrink K., Grabbe S., et al. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients. Exp Dermatol 2014, 23:202-204.
30. Obermajer N., Muthuswamy R., Lesnock J., Edwards R.P., Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells towards stable myeloid-derived suppressor cells. Blood 2011, 118:5498-5505.
31. Mao Y., Poschke I., Wennerberg E., Pico D.C.Y., Egyhazi B.S., Schultz I., et al. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 2013, 73:3877-3887.
32. Gehad A.E., Lichtman M.K., Schmults C.D., Teague J.E., Calarese A.W., Jiang Y., et al. Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas. J Invest Dermatol 2012, 132:2642-2651.
33. Yen B.L., Yen M.L., Hsu P.J., Liu K.J., Wang C.J., Bai C.H., et al. Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-Met and STAT3. Stem Cell Reports 2013, 1:139-151.
34. Mace T.A., Ameen Z., Collins A., Wojcik S., Mair M., Young G.S., et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 2013, 73:3007-3018.
35. Hochst B., Schildberg F.A., Sauerborn P., Gabel Y.A., Gevensleben H., Goltz D., et al. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. J Hepatol 2013, 59:528-535.
36. Huang A., Zhang B., Wang B., Zhang F., Fan K.X., Guo Y.J. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother 2013, 62:1439-1451.
37. Shen P., Wang A., He M., Wang Q., Zheng S. Increased circulating Lin CD33 HLA-DR myeloid-derived suppressor cells in hepatocellular carcinoma patients. Hepatol Res 2014, 44:639-650.
38. Albeituni S.H., Ding C., Yan J. Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J 2013, 19:490-501.
39. Ochoa A.C., Zea A.H., Hernandez C., Rodriguez P.C. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007, 13:721s-726s.
40. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005, 65:3044-3048.
41. Liu C.Y., Wang Y.M., Wang C.L., Feng P.H., Ko H.W., Liu Y.H., et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010, 136:35-45.
42. Jiao Z.J., Gao J.J., Hua S.H., Chen D.Y., Wang W.H., Wang H., et al. Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer. World J Gastroenterol 2012, 18:5454-5461.
43. Schmielau J., Finn O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001, 61:4756-4760.
44. Yu J., Du W., Yan F., Wang Y., Li H., Cao S., et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 2013, 190:3783-3797.
45. Mundy-Bosse B.L., Thornton L.M., Yang H.C., Andersen B.L., Carson W.E. Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol 2011, 270:80-87.
46. Hoechst B., Voigtlaender T., Ormandy L., Gamrekelashvili J., Zhao F., Wedemeyer H., et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009, 50:799-807.
47. Poschke I., Mao Y., Adamson L., Salazar-Onfray F., Masucci G., Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother 2012, 61:827-838.
48. Tadmor T., Fell R., Polliack A., Attias D. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol 2013, 31:325-331.
49. Weide B., Martens A., Zelba H., Stutz C., Derhovanessian E., Di Giacomo A.M., et al. Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells. Clin Cancer Res 2014, 20:1601-1609.
50. Jordan K.R., Amaria R.N., Ramirez O., Callihan E.B., Gao D., Borakove M., et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother 2013, 62:1711-1722.
51. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006, 66:9299-9307.
52. Iclozan C., Antonia S., Chiappori A., Chen D.T., Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 2013, 62:909-918.
53. Ko J.S., Zea A.H., Rini B.I., Ireland J.L., Elson P., Cohen P., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009, 15:2148-2157.
54. van Cruijsen H., van der Veldt A.A., Vroling L., Oosterhoff D., Broxterman H.J., Scheper R.J., et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008, 14:5884-5892.
55. Meyer C., Cagnon L., Costa-Nunes C.M., Baumgaertner P., Montandon N., Leyvraz L., Cagnon L., et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014, 63:247-257.
56. Wang Z., Zhang Y., Liu Y., Wang L., Zhao L., Yang T., et al. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients. J Immunother 2014, 37:43-50.
57. Annels N.E., Shaw V.E., Gabitass R.F., Billingham L., Corrie P., Eatock M., et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol Immunother 2014, 63:175-183.
58. Chandra D., Gravekamp C. Myeloid-derived suppressor cells: Cellular missiles to target tumors. Oncoimmunology 2013, 2:e26967.
59. Srivastava M.K., Bosch J.J., Thompson J.A., Ksander B.R., Edelman M.J., Ostrand-Rosenberg S. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 2008, 57:1493-1504.
60. Ramachandran I.R., Martner A., Pisklakova A., Condamine T., Chase T., Vogl T., et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol 2013, 190:3815-3823.
61. Kalathil S., Lugade A.A., Miller A., Iyer R., Thanavala Y. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res 2013, 73:2435-2444.
62. Gorgun G.T., Whitehill G., Anderson J.L., Hideshima T., Maguire C., Laubach J., et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013, 121:2975-2987.